86 related articles for article (PubMed ID: 15670697)
1. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach.
Meyer PT; Elmenhorst D; Bier D; Holschbach MH; Matusch A; Coenen HH; Zilles K; Bauer A
Neuroimage; 2005 Feb; 24(4):1192-204. PubMed ID: 15670697
[TBL] [Abstract][Full Text] [Related]
2. Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: analyses based on venous blood sampling.
Meyer PT; Elmenhorst D; Zilles K; Bauer A
Synapse; 2005 Mar; 55(4):212-23. PubMed ID: 15668990
[TBL] [Abstract][Full Text] [Related]
3. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET.
Meyer PT; Bier D; Holschbach MH; Boy C; Olsson RA; Coenen HH; Zilles K; Bauer A
J Cereb Blood Flow Metab; 2004 Mar; 24(3):323-33. PubMed ID: 15091113
[TBL] [Abstract][Full Text] [Related]
4. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments.
Elmenhorst D; Kroll T; Wedekind F; Weisshaupt A; Beer S; Bauer A
J Nucl Med; 2013 Aug; 54(8):1411-9. PubMed ID: 23740103
[TBL] [Abstract][Full Text] [Related]
5. A1 adenosine receptor PET using [18F]CPFPX: displacement studies in humans.
Meyer PT; Elmenhorst D; Matusch A; Winz O; Zilles K; Bauer A
Neuroimage; 2006 Sep; 32(3):1100-5. PubMed ID: 16806981
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies.
Matusch A; Meyer PT; Bier D; Holschbach MH; Woitalla D; Elmenhorst D; Winz OH; Zilles K; Bauer A
Nucl Med Biol; 2006 Oct; 33(7):891-8. PubMed ID: 17045169
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET.
Bauer A; Holschbach MH; Cremer M; Weber S; Boy C; Shah NJ; Olsson RA; Halling H; Coenen HH; Zilles K
J Nucl Med; 2003 Oct; 44(10):1682-9. PubMed ID: 14530487
[TBL] [Abstract][Full Text] [Related]
8. 18F-CPFPX PET: on the generation of parametric images and the effect of scan duration.
Meyer PT; Elmenhorst D; Matusch A; Winz O; Zilles K; Bauer A
J Nucl Med; 2006 Feb; 47(2):200-7. PubMed ID: 16455624
[TBL] [Abstract][Full Text] [Related]
9. Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Zilles K; Bauer A
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1061-70. PubMed ID: 17242921
[TBL] [Abstract][Full Text] [Related]
10. Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18F-CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Bauer A
J Nucl Med; 2012 Nov; 53(11):1723-9. PubMed ID: 22966134
[TBL] [Abstract][Full Text] [Related]
11. Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans.
Meyer PT; Elmenhorst D; Boy C; Winz O; Matusch A; Zilles K; Bauer A
Neurobiol Aging; 2007 Dec; 28(12):1914-24. PubMed ID: 16996650
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the A(1)1 adenosine receptor positron emission tomography ligand [18F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX) in rodents and humans.
Bier D; Holschbach MH; Wutz W; Olsson RA; Coenen HH
Drug Metab Dispos; 2006 Apr; 34(4):570-6. PubMed ID: 16415116
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A(1) receptors in human brain and transfected CHO cells: Inhibition of [(3)H]CPFPX binding by adenosine and caffeine.
Elmenhorst D; Garibotto V; Prescher A; Bauer A
Neurosci Lett; 2011 Jan; 487(3):415-20. PubMed ID: 21056087
[TBL] [Abstract][Full Text] [Related]
14. Optimal duration of PET studies with 18F-fluoroethyl-diprenorphine.
Boecker H; Sprenger T; Henriksen G; Toelle TR; Spilker ME
J Nucl Med; 2005 Dec; 46(12):2092-6. PubMed ID: 16330575
[TBL] [Abstract][Full Text] [Related]
15. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion.
Bauer A; Langen KJ; Bidmon H; Holschbach MH; Weber S; Olsson RA; Coenen HH; Zilles K
J Nucl Med; 2005 Mar; 46(3):450-4. PubMed ID: 15750158
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A1 receptor mapping of the human brain by PET with 8-dicyclopropylmethyl-1-11C-methyl-3-propylxanthine.
Fukumitsu N; Ishii K; Kimura Y; Oda K; Sasaki T; Mori Y; Ishiwata K
J Nucl Med; 2005 Jan; 46(1):32-7. PubMed ID: 15632030
[TBL] [Abstract][Full Text] [Related]
17. Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis.
Boy C; Meyer PT; Kircheis G; Holschbach MH; Herzog H; Elmenhorst D; Kaiser HJ; Coenen HH; Haussinger D; Zilles K; Bauer A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):589-97. PubMed ID: 18000666
[TBL] [Abstract][Full Text] [Related]
18. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.
Pinborg LH; Adams KH; Svarer C; Holm S; Hasselbalch SG; Haugbøl S; Madsen J; Knudsen GM
J Cereb Blood Flow Metab; 2003 Aug; 23(8):985-96. PubMed ID: 12902843
[TBL] [Abstract][Full Text] [Related]
19. Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.
Mitkovski S; Villemagne VL; Novakovic KE; O'Keefe G; Tochon-Danguy H; Mulligan RS; Dickinson KL; Saunder T; Gregoire MC; Bottlaender M; Dolle F; Rowe CC
Nucl Med Biol; 2005 Aug; 32(6):585-91. PubMed ID: 16026705
[TBL] [Abstract][Full Text] [Related]
20. Simplifications in analyzing positron emission tomography data: effects on outcome measures.
Logan J; Alexoff D; Kriplani A
Nucl Med Biol; 2007 Oct; 34(7):743-56. PubMed ID: 17921027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
